In a series of 74 patients with hematological malignancies undergoing allogeneic bone marrow or peripheral blood stem cell transplants from an HLA-identical sibling donor, four developed diffuse alveolar hemorrhage (DAH) between days 0 and 23 post transplant. Diagnosis was made by the radiographic finding of diffuse bilateral lung opacities, and bloody lavage fluid on bronchoscopy. Two patients required mechanical ventilatory support. They were treated with methylprednisolone 0.25-1.5 g/day for at least 4 days with slow tapering thereafter. All patients showed an immediate response and two became long-term survivors with normal respiratory function. Two had a relapse of DAH, developed acute respiratory distress syndrome (ARDS) and died with multi-organ failure. Risk factors for DAH were one or more courses of intensive chemotherapy pretransplant vs no treatment or low-dose chemotherapy (4/4 DAH vs 23/70 no DAH; P = 0.015), and second transplants (2/2 DAH vs 1/70 with no DAH; P = 0.006). These results indicate that DAH is life-threatening but is potentially reversible by prompt treatment with high doses of steroids. Keywords: diffuse alveolar hemorrhage; corticosteroids Diffuse alveolar hemorrhage (DAH) is an uncommon but life-threatening complication of allogeneic marrow stem cell transplantation. The condition was first noted in autologous transplants for solid tumors.
Diffuse alveolar hemorrhage (DAH) is an uncommon but life-threatening complication of allogeneic marrow stem cell transplantation. The condition was first noted in autologous transplants for solid tumors. 1 It has also been reported following autologous and allogeneic BMT for hematological malignancies. 2, 3 The syndrome has a mortality of between 70 and 100% 2-9 and the etiology is not known. Standard management involves bronchoscopy for diagnosis and the exclusion of an infective cause and support with mechanical ventilation. We report four patients who developed DAH after allogeneic bone marrow stem cell transplants and their response to high-dose methylprednisolone.
Patients and methods
The study group includes all patients with hematological malignancies receiving bone marrow or peripheral blood stem cell transplants from an HLA-identical sibling between September 1993 and January 1998. Patients were treated under Institutional Review Board approved NIH study protocols (93-H-212, 94-H-092, 94-H-182 and 97-H-099), evaluating T cell-depleted bone marrow or peripheral blood stem cell transplants followed by T cell add-back beginning day 30 or 45 post transplant (for details see . During this time-period, four patients developed DAH. The diagnosis of DAH was established by a clinical picture of respiratory distress with hypoxemia, diffuse alveolar infiltrates on chest X-ray and the finding of bloody bronchial lavage fluid. Other causes of respiratory failure were excluded by microbial stains and culture of bronchioalveolar lavage (BAL) fluid for bacteria, fungi and viruses. In addition, the lavaged cells were examined for cytopathic changes indicative of viral infection. Mechanical ventilation and aggressive supportive care was carried out in the intensive care unit as needed.
Statistics
Fisher's exact test was used to calculate significant differences between discontinuous variables in DAH and non-DAH patients. Table 1 shows the clinical characteristics and laboratory findings in four patients developing DAH. All patients had received either intensive chemotherapy prior to transplant or developed DAH following a second marrow stem cell transplant. DAH developed after neutrophil recovery in three of the four patients.
Results

DAH
Case histories UPN 025:
This 23-year-old man was diagnosed with chronic myeloid leukemia (CML) in chronic phase in 1994. He was treated initially with hydroxyurea and referred for BMT. At the time of transplant his disease had progressed to an accelerated phase. He was given cyclophosphamide 120 mg/kg followed by total body irradiation 1360 cGy given in eight fractions over 4 days and received a BMT from his HLA-identical brother. His post-transplant course was uncomplicated but 7 months later he relapsed into accelerated phase CML. After failing to respond to donor lymphocyte transfusions and interferon, he was prepared for a second transplant using Ara-C 3 g/m 2 ϫ 4 doses over 2 days, daunorubicin 30 mg/m 2 ϫ 2 doses and busulphan 16 mg/kg over 4 days. He received an unmanipulated peripheral blood progenitor cell (PBPC) transplant from the original donor. Engraftment occurred promptly with a neutrophil count of Ͼ0.5 ϫ 10 9 /l on day 11. On day 14 he developed dyspnoea and cough, he became tachypnoeic with a respiratory rate of 48/min. He was transferred to the intensive care unit and oxygen was supplied by facemask. A pulmonary artery catheter was inserted for central hemodynamic monitoring. An arterial blood gas obtained while receiving supplemental oxygen by face showed a pH of 7.48, pO 2 67 and pCO 2 20 mm Hg. Bronchoscopy and lavage revealed bloody fluid bilaterally with no intrabronchial lesions. Cultures from blood and BAL were negative. He was given methylprednisolone sodium succinate 1 g intravenously (i.v.) daily for 5 days and 0.5 g for 2 days with subsequent tapering. His respiratory function improved within 48 h, but 8 days later (day 22 post BMT) he deteriorated, coincident with reducing the steroid dose. High-dose methylprednisolone, 1.5 g daily for 3 days, 1 g daily for 3 days, and 0.5 g daily for 3 days with subsequent tapering, was reinstated and his condition rapidly improved. Oxygen supplementation was slowly withdrawn and steroids were discontinued on day 53 post BMT. Chest radiographs showed complete resolution of the infiltrates and no further respiratory complications developed. He remained well until a further leukemic relapse occurred. He died with leukemic relapse 487 days following the second transplant.
UPN 42:
A 42-year-old woman developed acute myeloblastic leukemia (AML) M1. Remission was induced with a standard '3 ϩ 7' combination of daunorubicin and Ara-C. She received further consolidation and maintenance chemotherapy but relapsed 12 months later. Remission was reinduced with a combination of mitoxantrone and etoposide. Six months later she relapsed again. Remission was reinduced with further mitoxantrone etoposide and intermediate-dose Ara-C. A third relapse occurred 7 months later, successfully reinduced with the same combination. She was referred for BMT in fourth remission. The preparative regimen consisted of cyclophosphamide 120 mg/kg and total body irradiation 1360 cGy in eight fractions over 4 days followed by a BMT from her HLA-identical sister. Hematological recovery occurred with a rise in neutrophils to 0.5 ϫ 10 9 /l by day 19. On day 23 she developed dyspnoea, dry cough and low-grade fever. An arterial blood gas while receiving supplemental O 2 showed a pH of 7.4, pCO 2 50 and pO 2 of 60 mm Hg. A chest radiograph showed bilateral diffuse opacities. Her condition deteriorated and she was transferred to the intensive care unit. Oxygen supplementation was initiated by face mask at an FiO 2 of 60%. A pulmonary artery catheter was inserted for central hemodynamic monitoring. Bronchoscopy revealed bloody lavage fluid with no intrabronchial lesions. Cultures of blood and BAL were negative. She was given methylprednisolone sodium succinate 1 g i.v. daily for 4 days, 0.5 g for 2 days with subsequent tapering of the dose. She responded rapidly with improvement in ventilatory capacity and chest radiograph appearance in 48 h. The steroid dose was rapidly reduced and oxygen supplementation was progressively withdrawn over the following week with no residual respiratory deficit. On day 57 post BMT while taking 20 mg/prednisolone daily she developed grade i.v. acute skin graft-versus-host disease and was treated again with high-dose steroids. Her GVHD responded slowly to treatment and she remained well and in remission until succumbing from septic shock and pseudomonas pneumonia on day 360 post transplant.
UPN 055:
A 23-year-old woman developed acute lymphoblastic leukemia (Ph chromosome negative, CALLA positive) during the third trimester of pregnancy. After a delay, during which time she delivered a healthy infant, remission was achieved with a standard combination of daunorubicin vincristine, prednisone and l-asparaginase. Sixteen months later she relapsed on maintenance therapy and a second remission was achieved using vincristine, prednisone and daunorubicin. She was then referred for bone marrow transplantation. The preparative regimen consisted of etoposide 500 mg/m 2 , total body irradiation 1360 cGy in eight fractions over 4 days and cyclophosphamide 120 mg/kg, followed by BMT from her HLAidentical sister. Engraftment was prompt, with neutrophil recovery to 0.5 ϫ 10 post transplant she developed respiratory distress, became tachypnoeic with a respiratory rate of 55/min. She became hypoxemic with 95% oxygen saturation on 3 l/min O 2 and a chest radiograph showed bilateral diffuse infiltrates. She was transferred to the intensive care unit and was supported with mechanical ventilation. A pulmonary artery catheter was inserted for central hemodynamic monitoring. Bronchoscopy revealed bloody lavage fluid with no intrabronchial lesions. Cultures of blood and BAL were negative. She was given methylprednisolone sodium succinate 2 g i.v. for 1 day, 1 g daily for 4 days and 0.5 g for 3 days with subsequent tapering. On day 31 post transplant after an initial clinical and radiographic improvement and decreased mechanical ventilatory support, she had a relapse of alveolar hemorrhage diagnosed by bronchoscopy with lavage. High-dose methylprednisolone was restarted but with less response. She developed further episodes of alveolar hemorrhage and died on day 44 post transplant with increasing lung stiffness, ventilatory difficulty and multiorgan failure.
UPN 072:
A 42-year-old woman was diagnosed in 1996 with AML M5. Remission was achieved with a standard 3ϩ7 regimen of daunorubicin and Ara-C. She received six courses of consolidation treatment with Ara-C and was referred for bone marrow transplant. The preparative regimen consisted of etoposide 500 mg/m 2 , total body irradiation 1360 cGy in eight fractions over 4 days and cyclophosphamide 120 mg/kg followed by a T celldepleted PBPC transplant from her HLA-identical brother. Engraftment was prompt with neutrophil recovery to 0.5 ϫ 10 9 /l neutrophils by day 10. Her post-transplant course was complicated by cytomegalovirus (CMV) reactivation for which she received gancyclovir. Foscarnet was substituted later because of pancytopenia. She became CMV antigen negative by day 80 post transplant. Six months post transplant she developed pancytopenia with marrow aplasia and graft failure was diagnosed by donorrecipient chimerism studies. She was reconditioned with a combination of cyclophosphamide 120 mg/kg, ATG 40 mg/m 2 for 4 days and fludarabine 25 mg/m 2 ϫ 5 days. She tolerated the preparative regimen well, but on the day of transplant of unmanipulated PBPC from her original donor, she developed fever (38.3°C), dyspnoea, tachypnoea and diffuse infiltrates on the chest radiography. The respiratory rate was 45/min but she maintained an O 2 saturation of 97% on 2 l of supplemental oxygen. She was transferred to the intensive care unit where bronchoscopy revealed bloody lavage fluid with no intrabronchial lesions. Oxygen supplementation was given by face mask and was adjusted to maintain adequate oxygenation. Methylprednisolone sodium succinate 0.5 g i.v. daily for 2 days and 0.25 g for 1 day were given. On day 3 her respiratory status deteriorated and respiratory support with mechanical ventilation was initiated. Methylprednisolone was given at 0.8 g i.v. daily for 2 days with subsequent tapering. Her clinical and radiographic sign improved and mechanical ventilation was discontinued on day 8. On day 7 cultures of BAL subsequently yielded CMV and gancyclovir was started. Further tests for CMV culture and antigenemia were all negative. On day 10 she relapsed with further hemorrhage confirmed by bronchoscopy. High-dose methylprednisolone was restarted but with no response. She developed progressive lung stiffness and decreased diffusion capacity and died 19 days post transplant with respiratory and multiorgan failure.
Factors associated with DAH
Patient and treatment characteristics of four patients with DAH are compared with 70 patients who did not develop DAH (Table 2 ). Patients with DAH had received significantly more chemotherapy than those who did not develop DAH (P = 0.015). Two of the four patients with DAH had received a second transplant compared with 1/70 not developing DAH (P = 0.006). In other respects, patients with DAH did not differ significantly from those not developing DAH.
Discussion
DAH is a life-threatening complication of high-dose chemoradiotherapy and bone marrow stem cell transplantation. It is described most commonly after autologous BMT but can occur after allogeneic BMT. The incidence of DAH after autologous BMT has been reported to be as high as 14%. [4] [5] [6] [7] In this series of T cell-depleted allograft recipients the incidence was 5.4%. DAH occurred as early as the day of transplant and up to 23 days after transplant, in three patients occurring after neutrophil recovery. The cause of DAH is not understood. Radiation toxicity, drug toxicity, thrombocytopenia, infection and neutrophil influx into the lung have all been implicated in the pathogenesis of DAH. 6, 9 Autopsy findings in BMT patients dying with DAH reveal diffuse alveolar damage, alveolar desquamation and hyaline membrane formation, findings that are characteristic of the acute respiratory distress syndrome. 1 In our series there appeared to be a correlation between the intensity of prior chemotherapy and radiation treatment and the risk of developing DAH. All patients were thrombocytopenic at the time of DAH onset (Table 3) . It is therefore possible that thrombocytopenic pulmonary hemorrhage may be the initiating event for DAH in patients with chemoradiotherapy-associated lung injury. Lung damage may be enhanced by recovering neutrophils. The normal prothrombin and partial thromboplastin times at onset of DAH in all patients argue against coagulopathy being an initiating factor in DAH (Table 2) . Age has been suggested to be a risk factor in DAH but there was no significant difference in our series with the non-DAH group (median age 33 vs 39 years for controls). One report found an association of later occurring DAH (days 20-28 post BMT) with microangiopathic changes accompanied by renal and cerebral dysfunction. 8 None of the patients in our series had microangiopathy, nor renal or cerebral complications. In three of the patients described here, no contributing pathogen could be implicated in the pathogenesis of DAH. In UPN 72 it is difficult to assess the role of CMV in the pathology of the alveolar hemorrhage. Firstly, the patient responded to steroids before gancyclovir was instituted, second, CMV was only isolated on one occasion and third, alveolar hemorrhage is not a feature of CMV pneumonia. In the absence of a clear pathophysiology, treatment of DAH is empirical. Treatment with steroids may be beneficial 4,5 but overall mortality from this complication remains high even in recent analyses. 13 We chose to use high doses of methylprednisolone in an attempt to reduce a possible acute inflammatory response to hemorrhage. Treatment was clearly effective in rapidly reversing clinical and radiographic findings and two patients had complete resolution of DAH and a return to normal pulmonary function. However, relapse of DAH with subsequent refractoriness to further steroid treatment was a prominent feature in our patients. Treatment failure in UPN 072 may have been in part related to instituting steroids at too low a dose and reducing treatment too rapidly. This suggests that the best approach to DAH is to first diagnose and exclude other causes by bronchoscopy with BAL, institute mechanical ventilation support if required and treat with methylprednisolone at high doses of at least 1 g/m 2 /day. To avoid relapse of DAH it may be necessary to continue high doses of steroids for at least 1 week after a response. While these observations are preliminary, they suggest that DAH is a reversible complication of marrow stem cell transplantation. Future efforts should focus on determining the optimum dose and duration of steroid treatment and at understanding the underlying etiology.
